Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by educational grants from Celgene Corporation, Genentech, Lilly USA, LLC, and Novartis Pharmaceuticals Corporation.
November 9, 2013 Crowne Plaza® Times Square - Manhattan New York, NY
The 8thAnnual New York Lung Cancer Symposium® is a one-day meeting which will serve as an update on advances in the field and will focus on the future of lung cancer treatment including: molecular subsets, targeted agents in development, treatment options in early stage, screening, the ongoing guideline debate, and a look forward from the experts.
Participants will learn from engaging presentations delivered by thought leaders and by reviewing and discussing realistic and complex scenarios, sharing clinical experiences, understanding well-established and emerging unmet therapeutic opportunities, solving clinical problems, and clarifying best practices. Participants will actively respond to and interact with the faculty through informal questions and open discussion, and as a result of this approach will leave with a higher level of understanding than they would otherwise achieve.
This educational activity is directed toward medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists involved in the treatment and management of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lung cancer may also participate.
Disclosure Policy and Conflict of Interest (COI)
As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines "relevant financial relationships" as financial relationships in any amount occurring within the past 12 months that create a COI.
Additionally, PER® is required by ACCME to resolve all COI. We have identified and resolved all COI prior to the start of this activity by using a multi-step process.
Faculty and Staff Disclosure
The following individuals have no relevant financial relationships with commercial interests to disclose:
Jorge E. Gomez, MD and Natasha B Leighl, BSc, MD, MSc.
The staff of Physicians' Education Resource®, LLC: Leigh Anne Bongiovanni; Ann C. Lichti, CCMEP; Dru Dace, PhD; and Megan O'Connell.
The following individuals have relevant financial relationships with commercial interests to disclose:
Abraham Chachoua, MD —Speaker’s Bureau: Eli Lilly; Richard J. Gralla, MD —Consultant: Eisai; Eli Lilly; Helsinn; Merck; Other Support: Lectures sponsored by Eisai; Helsinn; Merck; Balazs Halmos, MD —Grant/Research Support: Eli Lilly; Roche; Astex; Daiichi; Boehringer-Ingelheim; Bristol-Myers-Squibb; Merck; Astra-Zeneca; Oncothyreon; Astellas; Pfizer; Mirati; Harry D. Harper, MD – Speaker’s Bureau: Eli Lilly; Mark G. Kris, MD —Grant/Research Support: Pfizer Inc.; POMA; Boehringer-Ingelheim; Consultant: Novartis Pharmaceuticals Corporation; Pfizer Inc.; Genentech/Roche; Boehringer-Ingelheim; Benjamin P. Levy, MD —Consultant: Genentech; Pfizer Inc.; Speaker’s Bureau: Eli Lilly; Genentech; Pfizer Inc.; Roman Perez-Soler, MD —Speaker’s Bureau: Eli Lilly; Genentech; Bilal Piperdi, MD —Consultant: Amgen; Speaker’s Bureau: Genentech/Roche; Celgene Corporation; Merck; Pfizer, Inc.; Harry Raftopoulos, MD — Grant/Research Support: Novartis Pharmaceuticals Corporation; Roche; Pfizer Inc.; Eisai; Consultant: Merck; Gregory J. Riely, MD, PhD —Grant/Research Support: Chugai/Roche; Infinity; Pfizer; Novartis; Merk; Millennium; Consultant: Ariad; Naiyer A. Rizvi, MD —Grant/Research Support: Bristol-Myers-Squibb; Roche/Genentech; Medimmune; Merck; Consultant: Bristol-Myers-Squibb; Roche/Genentech; Medimmune; Charles M. Rudin, MD, PhD —Consultant: Celgene Corporation; Bryan J. Schneider, MD —Grant/Research Support: Celgene Corporation; Eli Lilly; Boehringer-Ingelheim; Consultant: Genentech; Speaker’s Bureau: Genentech; Pfizer Inc.; Alice T. Shaw, MD, PhD —Consultant: Pfizer Inc.; Novartis Pharmaceuticals Corporation; Ariad; Genentech; Steven E Vogl, MD —Stock/Shareholder: Amgen; Bristol-Myers-Squibb; Other Support: Advisory Board Celgene Corporation
Off-Label Disclosure and Disclaimer
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
You must be logged in to PER to register for this meeting